LGALS3 and diabetes mellitus: In the TOPCAT trial spironolactone appeared to alter the determinants of extracellular matrix remodeling in an anti-fibrotic fashion in patients with diabetes, reflected by changes in hs-TnT and TIMP-1 levels but not in Gal-3 over time [149].